EA201890325A1 - PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR APPLICATION FOR THE TREATMENT OF INFLAMMATORY DISEASES - Google Patents

PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR APPLICATION FOR THE TREATMENT OF INFLAMMATORY DISEASES

Info

Publication number
EA201890325A1
EA201890325A1 EA201890325A EA201890325A EA201890325A1 EA 201890325 A1 EA201890325 A1 EA 201890325A1 EA 201890325 A EA201890325 A EA 201890325A EA 201890325 A EA201890325 A EA 201890325A EA 201890325 A1 EA201890325 A1 EA 201890325A1
Authority
EA
Eurasian Patent Office
Prior art keywords
interleukin
receptor
peptide inhibitors
treatment
application
Prior art date
Application number
EA201890325A
Other languages
Russian (ru)
Other versions
EA035733B9 (en
EA035733B1 (en
Inventor
Грегори Борн
Сяоли Чэн
Брайан Трой Фредерик
Цзе Чжан
Динеш В. Пател
Дэвид Лю
Ашок Бхандари
Original Assignee
Протагонист Терепьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/en
Application filed by Протагонист Терепьютикс, Инк. filed Critical Протагонист Терепьютикс, Инк.
Publication of EA201890325A1 publication Critical patent/EA201890325A1/en
Publication of EA035733B1 publication Critical patent/EA035733B1/en
Publication of EA035733B9 publication Critical patent/EA035733B9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение предусматривает новые пептидные ингибиторы рецептора интерлейкина-23 и связанные с ними композиции и способы применения этих пептидных ингибиторов для лечения или предупреждения ряда заболеваний и нарушений, в том числе воспалительных заболеваний кишечника.The invention provides for new peptide inhibitors of the interleukin-23 receptor and related compositions and methods for using these peptide inhibitors for treating or preventing a number of diseases and disorders, including inflammatory bowel diseases.

EA201890325A 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases EA035733B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (3)

Publication Number Publication Date
EA201890325A1 true EA201890325A1 (en) 2018-06-29
EA035733B1 EA035733B1 (en) 2020-07-31
EA035733B9 EA035733B9 (en) 2021-01-14

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890325A EA035733B9 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Country Status (23)

Country Link
EP (1) EP3341011A4 (en)
JP (1) JP6858174B2 (en)
KR (1) KR102513978B1 (en)
CN (1) CN108348580B (en)
AU (1) AU2016293619B2 (en)
BR (1) BR112018000691A2 (en)
CA (1) CA2991984A1 (en)
CL (3) CL2018000128A1 (en)
CO (1) CO2018000349A2 (en)
CR (1) CR20180029A (en)
DO (1) DOP2018000010A (en)
EA (1) EA035733B9 (en)
EC (1) ECSP18002929A (en)
HK (2) HK1257747A1 (en)
IL (1) IL256827A (en)
MX (1) MX2018000542A (en)
NI (1) NI201800008A (en)
PE (1) PE20180571A1 (en)
PH (1) PH12018500086A1 (en)
SG (1) SG10201912066SA (en)
SV (1) SV2018005614A (en)
UA (1) UA123772C2 (en)
WO (1) WO2017011820A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102406771B1 (en) 2012-06-13 2022-06-13 인사이트 홀딩스 코포레이션 Substituted tricyclic compounds as fgfr inhibitors
HUE057168T2 (en) 2013-03-15 2022-04-28 Protagonist Therapeutics Inc Hepcidin analogues and uses thereof
EP3318564B1 (en) 2013-04-19 2021-07-28 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
NZ726337A (en) 2014-05-16 2023-10-27 Protagonist Therapeutics Inc Α4β7 integrin thioether peptide antagonists
CN107206254B (en) 2014-07-17 2021-08-24 领导医疗有限公司 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel disease
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
EP3200812B8 (en) 2014-10-01 2021-04-28 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2751669T3 (en) 2015-02-20 2020-04-01 Incyte Corp Bicyclic heterocycles as FGFR inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3432906A4 (en) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. Methods for synthesizing alpha4beta7 peptide antagonists
WO2018136646A1 (en) * 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
CA3073806A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
DK3788047T3 (en) 2018-05-04 2024-09-16 Incyte Corp Solid forms of an FGFR inhibitor and methods of making the same
MA52493A (en) 2018-05-04 2021-03-10 Incyte Corp FGFR INHIBITOR SALTS
JP2021530477A (en) * 2018-07-12 2021-11-11 プロタゴニスト セラピューティクス， インコーポレイテッド Peptide inhibitors of the interleukin-23 receptor and its use for the treatment of inflammatory diseases
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110015978B (en) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022000328A2 (en) 2019-07-10 2022-03-15 Protagonist Therapeutics Inc Interleukin-23 receptor peptide inhibitors and their use to treat inflammatory diseases
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
CN115151539A (en) 2019-12-04 2022-10-04 因赛特公司 Derivatives of FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3168135A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11939361B2 (en) * 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor
JP2024513575A (en) 2021-04-12 2024-03-26 インサイト・コーポレイション Combination therapy including FGFR inhibitor and Nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2024000761A (en) * 2021-07-14 2024-04-18 Janssen Biotech Inc Bicyclic peptide inhibitors of interleukin-23 receptor.
KR20240111800A (en) 2021-12-01 2024-07-17 질랜드 파마 에이/에스 Peptide inhibitors of the interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (en) * 2022-03-17 2023-11-07 北京大学 Staple peptide, preparation method and pharmaceutical application thereof
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists
US20240218014A1 (en) * 2022-11-21 2024-07-04 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
WO2024155547A2 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
WO2024163643A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
CN101790538B (en) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 Ucagon/glp-1 receptor co-agonists
CN101990547A (en) * 2007-07-06 2011-03-23 瓦勒瑞萨欣Hsj有限合伙公司 Il-23 receptor antagonists and uses thereof
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CN107206254B (en) * 2014-07-17 2021-08-24 领导医疗有限公司 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel disease

Also Published As

Publication number Publication date
CO2018000349A2 (en) 2018-07-10
BR112018000691A2 (en) 2018-09-18
WO2017011820A2 (en) 2017-01-19
HK1257747A1 (en) 2019-10-25
SG10201912066SA (en) 2020-02-27
CN108348580A (en) 2018-07-31
ECSP18002929A (en) 2018-03-31
JP2018522008A (en) 2018-08-09
UA123772C2 (en) 2021-06-02
AU2016293619A1 (en) 2018-02-01
EA035733B9 (en) 2021-01-14
NI201800008A (en) 2018-06-29
CL2018003322A1 (en) 2019-01-18
WO2017011820A3 (en) 2017-02-23
PE20180571A1 (en) 2018-04-04
KR20180030663A (en) 2018-03-23
MX2018000542A (en) 2018-06-27
CL2021000343A1 (en) 2021-08-06
CA2991984A1 (en) 2017-01-19
EA035733B1 (en) 2020-07-31
CN108348580B (en) 2022-05-10
KR102513978B1 (en) 2023-03-27
IL256827A (en) 2018-03-29
AU2016293619B2 (en) 2021-02-25
EP3341011A4 (en) 2019-02-20
JP6858174B2 (en) 2021-04-14
CR20180029A (en) 2018-06-05
DOP2018000010A (en) 2018-03-30
CL2018000128A1 (en) 2018-06-15
SV2018005614A (en) 2018-05-22
EP3341011A2 (en) 2018-07-04
PH12018500086A1 (en) 2018-07-30
HK1259149A1 (en) 2019-11-29

Similar Documents

Publication Publication Date Title
EA201890325A1 (en) PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR APPLICATION FOR THE TREATMENT OF INFLAMMATORY DISEASES
EA201891199A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201891202A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201891201A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890047A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890048A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890050A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890049A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
EA201890051A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
AR119389A1 (en) INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
EA201791874A1 (en) FLUORINATED INHIBITORS OF LYZYLOXIDE-LIKE ENZYME-2 AND THEIR APPLICATION
EA201691134A1 (en) NEW GLUTAMINASE INHIBITORS
BR112016022855A2 (en) compositions and methods for modulating pkk expression
EA201691516A1 (en) DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA
EA201691421A1 (en) HETEROARILES AND THEIR APPLICATION
EA201792604A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
EA201692091A1 (en) CHINOXALINE COMPOUNDS AND THEIR APPLICATION
MX2022000397A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases.
MX2020006365A (en) Quinazolinones as parp14 inhibitors.
CY1125150T1 (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
MX2018009325A (en) Compounds and methods of treating rna-mediated diseases.
EA202091337A1 (en) MYST FAMILY HISTONACETYLTRANSFERASE INHIBITORS
EA201890364A1 (en) COMPOUNDS SUITABLE FOR INHIBITING ROR-GAMMA-t
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM